fujirebio - MRCHF

MRCHF

Close Chg Chg %
22.36 -0.36 -1.61%

Closed Market

22.00

-0.36 (1.61%)

Volume: 1.07K

Last Updated:

Dec 2, 2025, 9:36 AM EDT

Company Overview: fujirebio - MRCHF

MRCHF Key Data

Open

$22.06

Day Range

22.00 - 22.06

52 Week Range

14.87 - 28.06

Market Cap

$1.25B

Shares Outstanding

56.82M

Public Float

51.59M

Beta

0.37

Rev. Per Employee

N/A

P/E Ratio

50.55

EPS

$0.44

Yield

379.00%

Dividend

$0.42

EX-DIVIDEND DATE

Sep 29, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

169.76

 

MRCHF Performance

1 Week
 
-6.26%
 
1 Month
 
-10.20%
 
3 Months
 
-12.87%
 
1 Year
 
N/A
 
5 Years
 
N/A
 

MRCHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About fujirebio - MRCHF

H.U. Group Holdings, Inc. provides the strategic planning, investor relations, public relations, and supervisory management of the entire group. It operates through the following segments: Testing and Related Services Business, Clinical Diagnostic Reagent Business, and Healthcare Related Services Business segments. The Testing and Related Services Business provides comprehensive testing services to medical institutions. The Clinical Diagnostics Reagent Business manufactures and sells clinical diagnostics. The Healthcare Related Services Business operates a sterilization-related business and a home and welfare equipment business. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

MRCHF At a Glance

H.U. Group Holdings, Inc.
Akasaka Intercity AIR
Tokyo, Tokyo 107-0052
Phone 81-3-6279-0801 Revenue 1.59B
Industry Medical/Nursing Services Net Income 18.10M
Sector Health Services Employees 5,444
Fiscal Year-end 03 / 2026
View SEC Filings

MRCHF Valuation

P/E Current 50.551
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 57.569
Price to Sales Ratio 0.654
Price to Book Ratio 1.137
Price to Cash Flow Ratio 6.37
Enterprise Value to EBITDA 8.913
Enterprise Value to Sales 0.847
Total Debt to Enterprise Value 0.429

MRCHF Efficiency

Revenue/Employee 292,822.444
Income Per Employee 3,325.542
Receivables Turnover 5.186
Total Asset Turnover 0.834

MRCHF Liquidity

Current Ratio 1.716
Quick Ratio 1.409
Cash Ratio 0.589

MRCHF Profitability

Gross Margin 25.23
Operating Margin 0.965
Pretax Margin 1.323
Net Margin 1.136
Return on Assets 0.948
Return on Equity 1.948
Return on Total Capital 1.21
Return on Invested Capital 1.329

MRCHF Capital Structure

Total Debt to Total Equity 63.197
Total Debt to Total Capital 38.724
Total Debt to Total Assets 30.993
Long-Term Debt to Equity 45.317
Long-Term Debt to Total Capital 27.769
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fujirebio - MRCHF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.43B 1.93B 1.64B 1.59B
Sales Growth
+15.51% -20.74% -14.89% -2.72%
Cost of Goods Sold (COGS) incl D&A
1.46B 1.30B 1.24B 1.19B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
130.16M 145.32M 144.33M 136.08M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
+3.46% -10.80% -4.54% -4.08%
Gross Income
969.60M 623.60M 396.01M 402.20M
Gross Income Growth
+40.05% -35.68% -36.50% +1.56%
Gross Profit Margin
+39.92% +32.39% +24.17% +25.23%
2022 2023 2024 2025 5-year trend
SG&A Expense
520.28M 451.07M 423.98M 386.81M
Research & Development
64.79M 70.51M 77.88M 71.46M
Other SG&A
455.48M 380.56M 346.09M 315.36M
SGA Growth
+14.88% -13.30% -6.01% -8.77%
Other Operating Expense
- - - 12.58M
-
Unusual Expense
48.74M 12.05M 1.89M 2.36M
EBIT after Unusual Expense
387.99M 160.48M (29.85M) 13.03M
Non Operating Income/Expense
(16.74M) 11.28M (20.10M) 11.93M
Non-Operating Interest Income
400.45K 1.79M 3.14M 3.33M
Equity in Earnings of Affiliates
(20.84M) (14.41M) (23.78M) (4.82M)
Interest Expense
3.52M 2.72M 2.76M 3.88M
Interest Expense Growth
+20.65% -22.54% +1.34% +40.50%
Gross Interest Expense
3.52M 2.72M 2.76M 3.88M
Interest Capitalized
- - - -
-
Pretax Income
367.73M 169.03M (52.69M) 21.09M
Pretax Income Growth
+87.30% -54.03% -131.17% +140.02%
Pretax Margin
+15.14% +8.78% -3.22% +1.32%
Income Tax
104.21M 53.35M (456.42K) 3.17M
Income Tax - Current - Domestic
88.14M 43.31M 26.44M 24.42M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
16.07M 10.04M (26.90M) (21.25M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(20.84M) (14.41M) (23.78M) (4.82M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
263.52M 115.68M (52.23M) 17.91M
Minority Interest Expense
- - 115.69K (190.23K)
-
Net Income
263.40M 115.68M (52.23M) 18.10M
Net Income Growth
+59.93% -56.08% -145.15% +134.66%
Net Margin Growth
+10.84% +6.01% -3.19% +1.14%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
263.40M 115.68M (52.23M) 18.10M
Preferred Dividends
- - - -
-
Net Income Available to Common
263.40M 115.68M (52.23M) 18.11M
EPS (Basic)
4.6234 2.033 -0.9182 0.3188
EPS (Basic) Growth
+60.05% -56.03% -145.16% +134.72%
Basic Shares Outstanding
56.97M 56.90M 56.89M 56.82M
EPS (Diluted)
4.6223 2.0329 -0.9182 0.3188
EPS (Diluted) Growth
+60.04% -56.02% -145.17% +134.72%
Diluted Shares Outstanding
56.98M 56.90M 56.89M 56.82M
EBITDA
566.89M 317.86M 116.36M 151.47M
EBITDA Growth
+55.34% -43.93% -63.39% +30.17%
EBITDA Margin
+23.34% +16.51% +7.10% +9.50%

Fujirebio in the News